Daily OCS dose reduction
Trial 3 primary endpoint: Patients treated with NUCALA achieved greater reductions in daily OCS dose (Weeks 20 to 24) while maintaining asthma control vs placebo (P=0.008).1
CI=confidence interval; ICS=inhaled corticosteroid;
OCS=oral corticosteroid; SOC=standard of care.
CI=confidence interval; ICS=inhaled corticosteroid;
OCS=oral corticosteroid; SOC=standard of care.
Real-world study of NUCALA: interim analysis at 1 year2
Secondary objective: Daily maintenance OCS dose* in OCS-dependent patient subgroup
75%
less OCS at Weeks 53-56
Median maintenance OCS dose, Weeks 53-56 (n=222) vs baseline (n=298): 2.5 mg/day vs 10 mg/day
50%
less OCS as early as Week 13
Median maintenance OCS dose, Weeks 13-16 (n=275) vs baseline (n=298): 5.0 mg/day vs 10 mg/day
All results are descriptive.
Real-World Study Limitations: Prespecified interim analysis of a single-arm, prospective, observational cohort study; may not reflect final results.
Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.
Baseline maintenance OCS dose (prednisone equivalent mg/day) defined as average daily dose in the 28 days prior to treatment index. Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.
Associated with elimination of daily OCS
In the pivotal OCS reduction study (Trial 3), 14% of patients treated with NUCALA vs 8% treated with placebo completely eliminated daily OCS use while maintaining asthma control at Weeks 20-24.1
Real-world study of NUCALA: interim analysis at 1 year2
43%
of patients
(95/222) completely eliminated daily OCS use*
Results are descriptive. Weeks 53-56.
Real-World Study Limitations: Prespecified interim analysis of a single-arm, prospective, observational cohort study; may not reflect final results.
Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.
